Almac Diagnostic Services recently announced that it has received CE marking for a next-generation sequencing-based diagnostic assay that will be used to determine molecular eligibility for enrolling patients in a pivotal Phase 2 portion of a cancer drug clinical trial.
Receipt of CE marking is further evidence of the utility of the test to support the European portion of the global clinical study, said Almac, which is based in
CE marking comes on the heels of the US Food and Drug Administration’s investigational device exemption approval of the assay.
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
